Literature DB >> 10563540

Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.

H G Dammann1, F Burkhardt.   

Abstract

AIMS: To determine the influence of recommended therapeutic doses of pantoprazole and omeprazole on meal-stimulated acid secretion.
METHODS: In this double-blind, placebo-controlled, three-period crossover study, 12 healthy male volunteers received 40 mg pantoprazole od, 20 mg omeprazole od or placebo at 08:00 h for 5 days in a randomized order. Meal-stimulated acid secretion was determined by means of a homogenized test meal, and intragastric titration on day 1, 4-6 h, 8-10 h, 16-18 h, and 24-26 h, and on days 3 and 5, 4-6 h after oral drug administration.
RESULTS: On day 1 (4-6 h after oral drug administration), meal-stimulated acid secretion was decreased by 36% and 24% after administration of 40 mg pantoprazole or 20 mg omeprazole, respectively. After 3 and 5 days of dosing, the decreases were 88% and 85% with 40 mg pantoprazole, and 70% and 74% with 20 mg omeprazole. At all measuring points during the 5-day dosing periods, 40 mg pantoprazole proved superior to 20 mg omeprazole in inhibiting meal-stimulated gastric acid secretion. The differences were statistically significant for pantoprazole on day 1, 24-26 h after oral drug administration and on day 3 (P = 0.0425 and P = 0.0244, respectively). On day 1, only pantoprazole was significantly better than placebo (P = 0.0210, 4-6 h after dosing; P = 0.0093, 8-10 h after dosing and P = 0.0068, 16-18 h after dosing).
CONCLUSION: Pantoprazole 40 mg is significantly more effective than omeprazole 20 mg in inhibiting meal-stimulated acid secretion. In addition, pantoprazole exhibits a more rapid onset of action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563540

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  10 in total

1.  Eriobotrya japonica seed extract and deep sea water protect against indomethacin-induced gastric mucosal injury in rats.

Authors:  Junko Yokota; Taisuke Kitaoka; Kohei Jobu; Daisuke Takuma; Atsuhide Hamada; Masahide Onogawa; Saburo Yoshioka; Shojiro Kyotani; Mitsuhiko Miyamura
Journal:  J Nat Med       Date:  2010-07-17       Impact factor: 2.343

2.  Pantoprazole may improve beta cell function and diabetes mellitus.

Authors:  F Inci; M Atmaca; M Ozturk; S Yildiz; R Koceroglu; R Sekeroglu; S H Ipekci; L Kebapcilar
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

Review 3.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

Review 4.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Evaluation of Antimicrobial Efficacy of Calcium Hydroxide along with Proton Pump Inhibitor against Enterococcus Faecalis.

Authors:  Namitha Divakar; Sunil Paramel Mohan; Manoj Kumar Pulyodan; Arun Tom; Deepthi Karukayil; Maya Somasundaram
Journal:  J Pharm Bioallied Sci       Date:  2020-08-28

Review 6.  The gastric HK-ATPase: structure, function, and inhibition.

Authors:  Jai Moo Shin; Keith Munson; Olga Vagin; George Sachs
Journal:  Pflugers Arch       Date:  2008-06-06       Impact factor: 3.657

Review 7.  Pharmacology of proton pump inhibitors.

Authors:  Jai Moo Shin; George Sachs
Journal:  Curr Gastroenterol Rep       Date:  2008-12

8.  Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.

Authors:  K Ashida; Y Sakurai; A Nishimura; K Kudou; N Hiramatsu; E Umegaki; K Iwakiri; T Chiba
Journal:  Aliment Pharmacol Ther       Date:  2015-07-22       Impact factor: 8.171

9.  Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Authors:  Kiyoshi Ashida; Katsuhiko Iwakiri; Naoki Hiramatsu; Yuuichi Sakurai; Tetsuharu Hori; Kentarou Kudou; Akira Nishimura; Eiji Umegaki
Journal:  World J Gastroenterol       Date:  2018-04-14       Impact factor: 5.742

Review 10.  Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.

Authors:  Tadayuki Oshima; Hiroto Miwa
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.